Key facts
- Glycologix’s last known valuation is $12.9M (Apr 2024).
- It has raised $7.5M across 4 recorded rounds; the latest was Seed Round ($800K) in Dec 2025.
- Notable investors include Cortado Ventures, InnoVentures Lab, National Institute of Diabetes and Digestive and Kidney Diseases, eCoast Angels.
- Glycologix has filed 3 Form Ds with the SEC since 2022, most recently Apr 2024 ($1.5M sold to 48 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Glycologix
Funding rounds
4 roundsAbout Glycologix
Developer of a clinical-stage biotechnology platform designed for soft tissue protection and repair. The company's lead asset is a cross-linked biopolymer delivered as a periodic bladder instillation that restores the urothelial protective layer with high tissue affinity and extended residence time, enabling healthcare professionals to address unmet medical needs in protecting and repairing soft tissues.
- Sector
- Healthcare
- HQ
- Beverly, MA, United States
- Founded
- 2016
- Employees
- 8
- Website
- glycologix.com/
- Ownership
- Privately Held (backing)
Glycologix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Glycologix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Glycologix in its N-PORT filings yet. We sweep new filings monthly.